Core Viewpoint - Novo Nordisk's stock price fell by 18% after disappointing guidance for fiscal year 2026, with Goldman Sachs suggesting that the market's reaction was excessive and that the current stock price reflects the lower end of the company's guidance range [1][4]. Group 1: Financial Guidance and Market Reaction - The company expects revenue for 2026 to decline by 5% to 13% at constant exchange rates, indicating significant pricing pressure and sales bottlenecks in the U.S. obesity drug market [3][5]. - Goldman Sachs noted that the lower end of the guidance implies approximately 13% and 14% downside risks to revenue and EBIT, respectively, aligning with the stock price drop [4]. - The guidance surprised the market, particularly regarding sales expectations, leading to a substantial adjustment in revenue and operating profit forecasts [4][5]. Group 2: U.S. Market Challenges - The decline in revenue is attributed to pricing pressures, slowing sales growth, and the impact of generics, contrasting with competitors like Eli Lilly, which provided a more optimistic sales outlook [5]. - Goldman Sachs significantly revised its forecast for U.S. Wegovy sales, reducing the expected growth from 20-25% to approximately 5%, with a projected 25% decline in sales revenue for 2026 [5]. Group 3: Oral Wegovy Performance - Despite the negative outlook, early performance of the oral version of Wegovy has been a bright spot, with around 50,000 prescriptions written in the U.S. market as of January 23, indicating strong demand [6][7]. - Approximately 45,000 of these prescriptions are self-pay, reflecting robust demand, and management expresses confidence in the product's competitive position [7]. Group 4: Key Catalysts and Pipeline Developments - 2026 is a critical year for Novo Nordisk's pipeline, with significant regulatory decisions expected [8]. - The FDA is anticipated to make a decision on high-dose semaglutide in Q1 2026, with ample production capacity ready for a swift U.S. launch upon approval [9]. - The regulatory decision for the combination drug CagriSema is expected by the end of 2026, with management indicating that initial trial results may not fully capture its weight loss potential [10].